Cardio Diagnostics Expands Access to Precision Cardiovascular Tests Through Atlas Healthcare Physicians

Cardio Diagnostics Holdings (NASDAQ: CDIO), an AI-powered precision cardiovascular medicine company, announced that Atlas Healthcare Physicians, an independent physician association serving managed care populations across Los Angeles and Orange counties, will provide coverage for the company’s Epi+Gen CHD and PrecisionCHD tests for eligible members with prior authorization. The coverage expands access to physician-ordered blood tests designed to assess coronary heart disease risk and support diagnosis and personalized treatment planning.

Cardio Diagnostics said Epi+Gen CHD evaluates a patient’s three-year risk of a coronary heart disease event, while PrecisionCHD helps diagnose coronary heart disease and identify its underlying molecular drivers. The company noted that both tests are noninvasive blood-based diagnostics that do not require fasting or radiation exposure, supporting broader adoption of precision cardiovascular medicine across community healthcare networks. This announcement is significant as it brings advanced, AI-driven cardiovascular testing to a broader patient population through an established physician network, potentially improving early detection and management of heart disease.

The partnership with Atlas Healthcare Physicians, which serves managed care populations, indicates a growing trend of integrating precision medicine into community healthcare settings. By providing coverage for these tests, Atlas Healthcare Physicians enables its members to benefit from personalized risk assessment and diagnosis without the need for invasive procedures. This could lead to more timely interventions and tailored treatment plans, ultimately improving patient outcomes and reducing healthcare costs associated with advanced cardiovascular disease.

Cardio Diagnostics’ tests are built on a proprietary Artificial Intelligence-driven Integrated Genetic-Epigenetic Engine, which analyzes genetic and epigenetic markers to provide insights into cardiovascular health. The company aims to make cardiovascular disease prevention, detection, and management more accessible and precise. This expansion into managed care networks aligns with that mission, potentially setting a precedent for other insurers and healthcare groups to adopt similar precision diagnostics.

The full press release is available at https://nnw.fm/EFQen. For more information about Cardio Diagnostics, visit the company’s newsroom at https://ibn.fm/CDIO. Forward-looking statements in this article are subject to risks and uncertainties as detailed in the company’s filings with the SEC, including its most recent Annual Report on Form 10-K and subsequent quarterly reports.